fbpx
Connect with us

CBD CONDITIONS & TREATMENTS

Chronic Pain and CBD Applications

Published

on

Pain is part of life. In many cases, pain is a blessing. For how else might we learn well not to touch a hot pan? In fact, there are stories of people who lack effective pain signaling. As one might expect, the life expectancy for such individuals is far below average. Pain is the body’s warning system. And without warnings, our chances of exposure to real danger increase dramatically.

However, when pain lingers around for weeks or months, it is a very different thing. In such cases, we call it “chronic pain”. And for many individuals, it’s an inescapable prison of torment.

The pharmaceutical industry, of course, has their solutions for the treatment of chronic pain. However, there’s an enormous drawback to their solutions: when regularly exposed to pharmaceutical pain solutions, the human body tends to build up a tolerance, an addiction, and a host of new maladies related to unwanted side effects such medications.

Enter CBD oil. This new player on the chronic pain playing field has the capacity to change everything.

CBD Enters the Chronic Pain Conversation

First, please understand, there is no silver bullet; no holy Grail; no panacea. That said, the introduction of CBD oil into the chronic pain treatment equation offers up tremendous new possibilities and tremendous hope.

By dramatic contrast to the pharmaceutical solutions currently defining this landscape, CBD doesn’t really have any material side effects when used properly, is non-psychoactive, nonaddictive, and rarely inspires the construction of an efficacy reducing tolerance in the human body.

Some folks still fail to see the difference between CBD and marijuana. And this is an important point. CBD is completely legal most everywhere, and it’s perfectly safe for kids. And, as noted above, it won’t get you “stoned”.

Chronic Pain and the Endocannabinoid System

As noted above, pain is the body’s way of alerting us to something that’s wrong. However, it’s possible for that system to get its wires crossed. And when that happens, pain that is ultimately derived from a simple injury can linger about and grow into a disruptive and debilitating health problem.

Those suffering from chronic pain also often experience disrupted sleeping patterns, chronic fatigue, and inconsistent appetite. Underneath all of this, it is thought, may well be problems of neurochemistry. But scientists don’t know for sure.

That said, what we do know is this: CBD has proven an effective agent in the battle against chronic pain. And that fact almost certainly points to the endocannabinoid system of the body.

As you may already be aware, the body comes equipped with the system built around cannabinoids. In fact, the body produces its own cannabinoids. And spread throughout the body are special receptor sites that, when triggered through reaction with cannabinoid molecules, are useful in the regulation of many bodily systems. But this system can experience malfunctions just like any other.

CBD can interrupt such malfunctions and set this important system back on track.

On the Research Front

Recent research has honed in on the rostral anterior cingulate cortex, or rACC. This appears to be the system most responsible for the management of how pain makes us feel. Through animal studies, mostly focused on rats, researchers have begun to test out how CBD can affect the processing that goes on in this system.

To cut to the chase, the data from such studies uniformly points toward the efficacy of CBD for diminishing the negative experience of pain. Naturally, these CBD pain studies are still in the early stages, and the medical establishment will need to see far more data before such treatment protocols are mainstreamed.

Additionally, given what we already know about CBD’s anti-inflammatory properties, it should come as no surprise that there is also plenty of research emerging to support the benefits of CBD for treating inflammatory pain.

One such study focused on rats suffering from chronic constriction of the sciatic nerve and associated neuropathic pain sensations. In this study, the rats involved received orally administrated daily CBD treatments. And what we found was remarkable: the study showed a material reduction in pain sensation between 1 to 2 weeks.

CBD for Chronic Pain: Conclusions

As discussed above, current pharmaceutical solutions for chronic pain have limited upside and a whole lot of potential downside, including tolerance and increased dosage needs, strong potential for addiction, and a host of unwanted side effects.

But those suffering from chronic pain have been stuck with a Hobson’s choice: be willing to suffer through those negatives, or continue to deal with the prison of torment they face on a daily basis as a sufferer of chronic pain, which includes side dishes such as fatigue, irritability, dizziness, difficulty sleeping, and poor nutrition through loss of appetite.

Hence, it should be clear just exactly why the introduction of CBD onto the scene can be such an important development for those currently fighting this war.

While the research community is firm in its insistence that the data on CBD for pain is far from complete, and more study is needed before it can become a mainstream solution, what we have seen so far is extremely promising. In addition, there is already a ton of anecdotal evidence suggesting that plenty of people are already finding some measure of relief from their pain through CBD oil.

CBD CONDITIONS & TREATMENTS

WeedMD Inc (OTCMKTS:WDDMF) Rolls Out Its Color Cannabis Brand For Adults

Published

on

WeedMD Inc (OTCMKTS:WDDMF) has announced the launch of its latest brand called Color Cannabis as a premium brand that targets adult users that want high-grade cannabis products.

The new Color Cannabis premium brand features numerous strains of cannabis that are presented in multiple formats. However, they are also developed such that they have a high level of quality as per the expectations of the target consumers. WeedMD’s new brand will only be available to a few distributors and retailers in Canada.

WeedMD plans to have the Color Cannabis-branded products in select stores as well as online availability by Mid-June. The company created the brand with a strategic aim at the diverse preference and tastes of the modern-day cannabis consumer.

“We worked with globally-renowned agency Sid Lee to launch Color – our first adult-use brand,” stated Brett Moon, the Senior Vice President of sales and marketing at WeedMD.

The Color Cannabis brand to mainly focus on a premium user experience

Mr. Moon also noted that Color Cannabis is designed to inspire customers to embrace life and their cannabis experience in personal and unique ways. Aside from being available in the form of dried premium flower, the new WeedMD brand also hosts new product formats over the next few months. Some of those products include gel capsules, oils and pre-rolls and they will be made available with the creation of more consumption formats.

WeedMD CEO Keith Merker stated that Color Cannabis’ goal is to grasp the progressive character, individuality, and imagination of cannabis users. The CEO noted that the goal of the brand is not to tell clients what they will feel but rather to experience the products for themselves. Merker also noted that the Color Cannabis launch represents a key milestone for the company.

WeedMD expects to juggle between the new adult cannabis brand and its medical cannabis pursuits. The company expects to produce about 150,000 kilograms through its 5.2 million square feet production capacity by 2020. The firm also expects to have enough room to handle production for medical cannabis, as well as recreational adult use. It plans to achieve this through its indoor and outdoor growth facilities.

Continue Reading

CBD CONDITIONS & TREATMENTS

HempAmericana Inc. (OTCMKTS:HMPQ) CEO Issues Explains The Company’s Expansion

Published

on

HempAmericana Inc. (OTCMKTS:HMPQ) CEO has issued a letter to shareholders addressing the expansion of the company following string orders.

HempAmericana has begun bottling of full-spectrum CBD distillate

In the letter to shareholders, the CEO indicated that the company has begun establishing growth momentum in its CBD oil production as well as the distribution business. The CEO stated that the company has started bottling of 500 mg as well as 1000 mg full spectrum CBD distillate in its ultramodern CBD production and extraction facility in Augusta Maine.

He added that the company’s initial production is expected to be around 2,000 bottles per day which will be increased gradually to around 8,000 bottles a day to meet demand. Currently, the company has more than 50,000 full spectrum distillate bottles that are ready to be shipped with tens of thousands expected to follow.

HempAmericana is equally bottling a 250 mg potency that is suitable for the CBD-for-pets market. On the high end, the CEO indicated that the company is bottling 2500 mg and 5000 mg but he asserted that they have the potential of replicating any formula.

The CEO further went on to explain that production will be distributed under the company’s proprietary brand “Weed Got Oil.” He added that the company is also pursuing an opportunity in the white label market for the quality full-spectrum distillate CBD Oil. Currently, there are over 400 brands in the CBD market with the majority turning to high capacity producers such as HempAmericana to build product inventory.

Relationship with Eagle Hemp

The company recently announced a relationship with Florida based Eagle Hemp for an initial purchase order as well as the establishment of connections for more orders in the future. The company anticipates strong demand that includes compensation for more production of CBD oil as well as its bottling technology. The first order will bring the company significant revenue input at no associated costs to labeling, bottling, and shipping.

The company’s production facility and lab are currently operating well with two bottling machines in operation. The CEO said that once they distill the interest into purchase orders they will communicate to shareholders.

Continue Reading

CBD CONDITIONS & TREATMENTS

Medmen Enterprises Inc. (OTCMKTS:MMNFF) Expands Its Footprint In California With Acquisition Of One Love

Published

on

MedMen Enterprises Inc. (OTCMKTS:MMNFF) has announced the signing of a definitive agreement for the acquisition of 100% interest in MattnJeremy, Inc. One Love Beach Club.

Acquisition of One Love

The acquisition enhances the company’s California footprint by adding a premier location that is positioned strategically between its LAX and Santa Ana locations. The One Love Beach Club is currently on a run-rate of around $6 million in gross revenue and has an unaudited EBITDA margin of about 29%.

MedMen CEO Adam Bierman stated that they were delighted to have Long Beach on bard as part of the MedMen family as the company continues its growth in the world’s leading cannabis market.

One love was founded back in 2009 and it is located in Long Beach at 2767 E Broadway between Belmont Shore and Downtown some blocks from the beach. Long Beach is located 20 miles from Los Angeles and it is the third largest city in Southern California behind San Diego and Los Angeles with a population of almost half a million.

The city is a prime location that offers attractions, oceanfront hotels, events, recreation activities, shopping, nightly entertainment, restaurants as well as art and culture. According to the Long Beach Convention & Visitors Bureau in 2018 there were approximately 7.9 million visitors who visited the city to attend various events and attractions.

The One Love owner and operator Abrams Family indicated that it had been exciting to have served the Long Beach community for the last ten years adding that they were looking forward to MedMen to continue offering the community with premium cannabis.

Details of the transaction

According to the details of the transaction MedMen is expected to pay around $13 million of which $1 million will be in cash at closing of the deal and $2 million in deferred cash. The rest of the $10 million shall be fulfilled in Class B Subordinate Voting shares. Completion of the transactions depends on regulatory approval by state and local authorities as well as other routine closing conditions. The deal is expected to be closed within 45 days.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories